share_log
Benzinga ·  Apr 29 06:32
FDA Approves X4 Pharmaceuticals' Xolremdi (Mavorixafor) Capsules For Use In Patients 12 Years Of Age And Older With WHIM Syndrome To Increase The Number Of Circulating Mature Neutrophils And Lymphocytes
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment